摘要
目的探讨胃苏颗粒联合美沙拉嗪治疗肠易激综合征的临床效果。方法选取2016年6月—2019年6月郑州市第九人民医院收治的104例肠易激综合征患者,随机分成对照组和治疗组,每组各52例。对照组患者口服美沙拉嗪肠溶片,0.5 g/次,3次/d,餐后整片吞服。治疗组在对照组基础上口服胃苏颗粒,1袋/次,3次/d,适量开水冲服。两组均连续治疗4周。观察两组临床疗效,比较两组治疗前后肠易激综合征–症状严重程度量表(IBS-SSS)评分、匹兹堡睡眠质量指数(PSQI)评分、肠易激综合征–生活质量量表(IBS-QOL)评分和相关血清学指标的变化情况。结果治疗组总有效率94.2%较对照组80.8%显著提高(P<0.05)。两组治疗后IBS-SSS中各项(腹胀程度、腹痛程度、腹痛频率等)评分及其总分均显著低于治疗前(P<0.05);但治疗组下降更显著(P<0.05)。与治疗前相比,两组治疗后PSQI总分均显著降低(P<0.05),而IBS-QOL总分均显著增高(P<0.05);且治疗后,治疗组患者PSQI总分显著低于对照组同期(P<0.05),IBS-QOL总分则显著更高(P<0.05)。治疗后两组患者血清肿瘤坏死因子(TNF)-α、白介素(IL)-1β、IL-6、丙二醛(MDA)水平均显著低于治疗前(P<0.05);且治疗组治疗后以上血清学指标水平均较对照组同期显著更低(P<0.05)。结论胃苏颗粒联合美沙拉嗪治疗肠易激综合征的整体疗效良好,可明显改善患者症状,缓解肠黏膜低度炎症状态,降低氧化应激损伤,提高患者睡眠质量及生命质量,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Weisu granules combined with mesalazine in treatment of irritable bowel syndrome.Methods 104 Patients with irritable bowel syndrome admitted to Ninth People's Hospital of Zhengzhou from June 2016 to June 2019 were randomly divided into treatment group(n=52)and control group(n=52).The control group was po administered with Mesalazine Enteric-coated Tablets swallow whole piece after meal,0.5 g/time,three times daily.The treatment group was po administered with Weisu Granules on the basis of the control group,1 bag/time,three times daily.All patients were treated for 4 weeks.The clinical efficacy of the two groups was observed,and the changes in irritable bowel syndrome-Symptom Severity Scale(IBS-SSS)score,Pittsburgh Sleep Quality Index(PSQI)score,Irritable bowel syndrome-Quality of Life Scale(IBS-QOL)score and related serological indicators before and after treatment were compared between the two groups.Results The total effective rate of 94.2%in the treatment group was significantly higher than 80.8%in the control group(P<0.05).After treatment,all the scores(degree of abdominal distension,degree of abdominal pain,frequency of abdominal pain,etc.)in IBS-SSS and their total scores were significantly lower than those before treatment(P<0.05).However,the reduction was more significant in the treatment group(P<0.05).Compared with before treatment,the total score of PSQI in both groups was significantly reduced after treatment(P<0.05),but the total score of IBS-QOL was significantly increased(P<0.05).After treatment,the total score of PSQI in the treatment group was significantly lower than that in the control group(P<0.05),and the total score of IBS-QOL was significantly higher(P<0.05).The serum levels of TNF-α,IL-1β,IL-6,and MDA in both groups were significantly lower than those before treatment(P<0.05).The serological indexes of the treatment group were significantly lower than those of the control group(P<0.05).Conclusion Weisu Granules combined with mesalazine has o
作者
郝红
赵宁民
张兵兵
张祖峰
李方
HAO Hong;ZHAO Ning-min;ZHANG Bing-bing;ZHANG Zu-feng;LI Fang(Department of Pharmacy,Ninth People's Hospital of Zhengzhou,Zhengzhou 450000,China;Department of Pharmacy,Henan Provincial People's Hospital,Zhengzhou 450003,China;Department of Digestive Medicine,Ninth People's Hospital of Zhengzhou,Zhengzhou 450000,China;Department of Internal Medicine,Ninth People's Hospital of Zhengzhou,Zhengzhou 450000,China)
出处
《现代药物与临床》
CAS
2020年第7期1368-1372,共5页
Drugs & Clinic
基金
河南省科技攻关计划项目(162102310287)。
关键词
胃苏颗粒
美沙拉嗪肠溶片
肠易激综合征
肠黏膜低度炎症反应
丙二醛
Weisu Granules
Mesalazine Enteric-coated Tablets
irritable bowel syndrome
low inflammation of intestinal mucosa
malondialdehyde(MDA)
